EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A reverse vaccinology approach identified novel recombinant tick proteins with protective efficacy against Rhipicephalus microplus infestation

Luísa N Domingues, Kylie G Bendele, Deanna M Bodine, Lénaïg Halos, Andre A Cutolo, Martin Liebstein, Justin Widener, Monica Figueiredo, Yovany Moreno, Christian Epe, Alvimar Jose da Costa, Lucas Vinícius Costa Gomes und 1 weitere

Ticks and Tick-borne Diseases · 2024

DOI: 10.1016/j.ttbdis.2024.102403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ticks and Tick-borne Diseases, 2024. Verfasst von Luísa N Domingues und 12 weiteren Autor:innen. Beteiligte Einrichtung: USDA-ARS Knipling-Bushland U. S. Livestock Insects Research Lab, 2700 Fredericksburg Road, Kerrville 78028, TX, USA. Hauptthemen laut MEDLINE: Rhipicephalus, Tick Infestations, Recombinant Proteins, Cattle Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: USDA Agricultural Research Service, Oak Ridge Institute for Science and Education, U.S. Department of Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cattle tick, Rhipicephalus microplus, causes significant economic losses to the cattle industry. Tick control is predominately achieved via pesticide applications. However, alternative control methods such as vaccines are needed due to the tick's capacity to quickly develop pesticide resistance and to combat tick-borne diseases. We used an in silico reverse vaccinology approach to evaluate and rank open reading frames (ORFs) from the tick's transcriptome for their potential use as anti-R. microplus vaccine antigens. We manually annotated the 200 highest ranked antigens and selected 10 transcript ORFs as vaccine antigen candidates for expression in Pichia pastoris or insect cells. Six of the ten candidate antigens could be successfully expressed and purified in vitro as recombinant proteins with > 1 mg quantity. RT-PCR confirmed the expression of all six transcripts in tick RNA. However, only three of the six transcripts' corresponding ORFs could be confirmed as present in tick tissue protein extracts. Only four of the six vaccine candidate antigens were successfully expressed and purified in sufficient quantity (> 10 mg) for immunogenicity and efficacy trials in cattle. These four were designated BI-TS002, BI-TS004, BI-TS008, and BI-TS009 and sufficient annotation existed that showed sequence similarity to serine‑rich adhesin for platelets, glycine-rich cell wall structural membrane protein, SWM-1 tick serine protease inhibitor, and venom-like dermonecrotic toxins from ticks and spiders, respectively. Cattle immunized with BI-TS004, BI-TS008 and BI-TS009 yielded a statistically significant difference in antibody response post-immunization. This difference was noted on Days 42, 56, 70, and 84 post-immunization for BI-TS008 and BI-TS009, but only on Day 56 for BI-TS004. BI-TS008 and BI-TS009, were formulated with adjuvant and cattle stall tests conducted over a 175 day period to evaluate efficacy against R. microplus infestations. Both an adjuvant only negative control group and a positive control group using the commercially available GAVAC anti-tick vaccine were used. Efficacy was determined by comparing number of engorged adult female ticks, total egg mass weight, and egg hatchability produced from the immunized group to corresponding data from the adjuvant only negative control group. Thus, effects on engorged adult tick number, reproductive capacity, and fertility were measured. Both initial (designated Phase 1 and calculated from tick collections of Days 60-94 days post-first immunization) and long-term (designated Phase 2 and calculated from tick collections of Days 152-175 post-first immunization) efficacies were determined. The overall Phase 1 trial efficacies of BI-TS008, BI-TS009, and GAVAC were 68.3 %, 48.5 %, and 70.7 %, respectively. The overall Phase 2 trial efficacies of BI-TS008, BI-TS009, and GAVAC were 64.4 %, -30.1 %, and 45.1 %, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhipicephalusTick InfestationsRecombinant ProteinsCattle DiseasesArthropod ProteinsVaccinesAnimalsCattleFemaleVaccinologyAntigensTick Control

Stichwörter der Autor:innen

Antigen discoveryIn silico anti-tick vaccine antigen discoveryIn vitro protein expressionIn vivo vaccine antigen efficacy trialRecombinant tick proteinReverse vaccinology

Substanzen

Recombinant ProteinsArthropod ProteinsVaccinesAntigens

Autor:innen und Institutionen

  • USDA-ARS Knipling-Bushland U. S. Livestock Insects Research Lab, 2700 Fredericksburg Road, Kerrville 78028, TX, USA.
  • USDA-ARS Knipling-Bushland U. S. Livestock Insects Research Lab, 2700 Fredericksburg Road, Kerrville 78028, TX, USA. Electronic address: kylie.bendele@usda.gov.
  • Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, Lyon 69007, France.
  • Boehringer Ingelheim Animal Health, Missouri Research Center, 6498 Jade Rd, Fulton 65251, MO, USA.
  • Boehringer Ingelheim Animal Health, 1730 Olympic Dr, Athens 30601, GA, USA.
  • Boehringer Ingelheim Animal Health, Binger Str. 173 Ingelheim 55216 Germany.

Förderung

  • USDA Agricultural Research Service
  • Oak Ridge Institute for Science and Education
  • U.S. Department of Energy
  • U.S. Department of Agriculture
  • Oak Ridge Associated Universities

Zitieren

APA

Domingues, L. N., Bendele, K. G., Bodine, D. M., Halos, L., Cutolo, A. A., Liebstein, M., Widener, J., Figueiredo, M., Moreno, Y., Epe, C., da Costa, A. J., Gomes, L. V. C., & Guerrero, F. D. (2024). A reverse vaccinology approach identified novel recombinant tick proteins with protective efficacy against Rhipicephalus microplus infestation. Ticks and Tick-borne Diseases. https://doi.org/10.1016/j.ttbdis.2024.102403

Vancouver

Domingues LN, Bendele KG, Bodine DM, Halos L, Cutolo AA, Liebstein M, et al. A reverse vaccinology approach identified novel recombinant tick proteins with protective efficacy against Rhipicephalus microplus infestation. Ticks and Tick-borne Diseases. 2024. doi:10.1016/j.ttbdis.2024.102403

BibTeX
@article{Domingues2024,
  author = {Domingues, Luísa N and Bendele, Kylie G and Bodine, Deanna M and Halos, Lénaïg and Cutolo, Andre A and Liebstein, Martin and Widener, Justin and Figueiredo, Monica and Moreno, Yovany and Epe, Christian and da Costa, Alvimar Jose and Gomes, Lucas Vinícius Costa and Guerrero, Felix D},
  title = {A reverse vaccinology approach identified novel recombinant tick proteins with protective efficacy against Rhipicephalus microplus infestation},
  journal = {Ticks and Tick-borne Diseases},
  year = {2024},
  doi = {10.1016/j.ttbdis.2024.102403}
}
Kostenlos starten →